全文获取类型
收费全文 | 11070篇 |
免费 | 896篇 |
国内免费 | 31篇 |
专业分类
耳鼻咽喉 | 125篇 |
儿科学 | 414篇 |
妇产科学 | 256篇 |
基础医学 | 1487篇 |
口腔科学 | 145篇 |
临床医学 | 1452篇 |
内科学 | 2174篇 |
皮肤病学 | 137篇 |
神经病学 | 936篇 |
特种医学 | 357篇 |
外科学 | 1672篇 |
综合类 | 178篇 |
一般理论 | 5篇 |
预防医学 | 1040篇 |
眼科学 | 248篇 |
药学 | 727篇 |
中国医学 | 19篇 |
肿瘤学 | 625篇 |
出版年
2021年 | 165篇 |
2020年 | 119篇 |
2019年 | 181篇 |
2018年 | 196篇 |
2017年 | 156篇 |
2016年 | 164篇 |
2015年 | 216篇 |
2014年 | 240篇 |
2013年 | 404篇 |
2012年 | 631篇 |
2011年 | 621篇 |
2010年 | 329篇 |
2009年 | 293篇 |
2008年 | 497篇 |
2007年 | 567篇 |
2006年 | 578篇 |
2005年 | 574篇 |
2004年 | 616篇 |
2003年 | 519篇 |
2002年 | 456篇 |
2001年 | 283篇 |
2000年 | 270篇 |
1999年 | 300篇 |
1998年 | 131篇 |
1997年 | 109篇 |
1996年 | 92篇 |
1995年 | 86篇 |
1994年 | 87篇 |
1993年 | 79篇 |
1992年 | 170篇 |
1991年 | 183篇 |
1990年 | 187篇 |
1989年 | 162篇 |
1988年 | 148篇 |
1987年 | 144篇 |
1986年 | 147篇 |
1985年 | 136篇 |
1984年 | 106篇 |
1983年 | 93篇 |
1982年 | 63篇 |
1981年 | 77篇 |
1980年 | 63篇 |
1979年 | 118篇 |
1978年 | 87篇 |
1977年 | 75篇 |
1976年 | 88篇 |
1975年 | 66篇 |
1974年 | 73篇 |
1973年 | 87篇 |
1972年 | 75篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
1.
Judith Brock Andreas Schmid Thomas Karrasch Petra Pfefferle Jutta Schlegel Inga Busse Annette Hauenschild Barbara Schmidt Maria Koukou Efthymia Arapogianni Andreas Schultz Miriam Thomalla Secil Akinci Johannes Kruse Winfried Padberg Andreas Schffler Jens Albrecht 《Clinical endocrinology》2019,91(3):400-410
2.
Sebastian Mondaca Walid K. Chatila David Bates Jaclyn F. Hechtman Andrea Cercek Neil H. Segal Zsofia K. Stadler Anna M. Varghese Ritika Kundra Marinela Capanu Jinru Shia Nikolaus Schultz Leonard Saltz Rona Yaeger 《Clinical colorectal cancer》2019,18(1):e39-e52
Background
Treatment of advanced anal squamous cell cancer (SCC) is usually with the combination of cisplatin and 5-fluorouracil, which is associated with heterogeneous responses across patients and significant toxicity. We examined the safety and efficacy of a modified schedule, FOLFCIS (leucovorin, fluorouracil, and cisplatin), and performed an integrated clinical and genomic analysis of anal SCC.Patients and Methods
We reviewed all patients with advanced anal SCC receiving first-line FOLFCIS chemotherapy – essentially a FOLFOX (leucovorin, fluorouracil, and oxaliplatin) schedule with cisplatin substituted for oxaliplatin – in our institution between 2007 and 2017, and performed deep sequencing to identify genomic markers of response and key genomic drivers.Results
Fifty-three patients with advanced anal SCC (48 metastatic; 5 unresectable, locally advanced) received first-line FOLFCIS during this period; all were platinum-naive. The response rate was 48% (95% confidence interval [CI], 32.6%-63%). With a median follow-up of 41.6 months, progression-free survival and overall survival were 7.1 months (95% CI, 4.4-8.6 months) and 22.1 months (95% CI, 16.9-28.1 months), respectively. Among all patients with advanced anal SCC that underwent sequencing during the study period, the most frequent genomic alterations consisted of chromosome 3q amplification (51%) and mutations in PIK3CA (29%) and KMT2D (22%). No genomic alteration correlated with response to platinum-containing treatment. Although there were few cases, patients with human papillomavirus-negative anal SCC did not appear to benefit from FOLFCIS, and all harbored distinct genomic profiles with TP53, TERT promoter, and CDKN2A mutations.Conclusions
FOLFCIS appears effective and safe as first-line chemotherapy in patients with advanced anal SCC and represents an alternative treatment option for these patients. 相似文献3.
4.
Gregory Guldner MD MS Jason Schultz BS Perry Sexton MD Corwyn Fortner BS Mark Richmond MD 《Academic emergency medicine》2003,10(2):134-139
OBJECTIVES: Physicians commonly use etomidate for adult rapid-sequence intubation (RSI), but the manufacturer does not recommend its use for children under 10 years of age due to a lack of data. The authors present their experience with etomidate for pediatric RSI in order to further develop its risk-benefit profile in this age group. METHODS: Trained abstractors reviewed the medical records for all children under 10 years old who received etomidate for RSI between July 1996 and April 2001. RESULTS: 105 children, with an average age of 3 (+/-2.9) years, received a median dose of 0.32 (+/-0.12) mg/kg of etomidate. The systolic blood pressure increased an average of 4 mm Hg (95% CI = -3.3 to 9.2); the diastolic blood pressure increased 7 mm Hg (95% CI = -3.1 to 11) within 10 minutes of receiving etomidate. The heart rate increased an average of 10 beats/min (95% CI = 4.0 to 17.4). Complications included three patients who vomited within 10 minutes of etomidate administration. There were no cases of documented myoclonus, status epilepticus, or new-onset seizures. Thirty-eight patients received corticosteroids during the hospital course, none for suspected adrenal insufficiency. Three patients died, all from severe brain injury. CONCLUSIONS: In children less than 10 years old, etomidate seems to produce minimal hemodynamic changes, and appears to have a low risk of clinically important adrenal insufficiency, myoclonus, and status epilepticus. The association between etomidate and emesis (observed in less than 3% of enrolled patients) remains unclear. For clinical situations in which minimal blood pressure changes during RSI are critical, etomidate appears to have a favorable risk-benefit profile for children under 10 years old. 相似文献
5.
Background
The prevalence of tobacco usage in Native American adults and adolescents is higher than any other racial or ethnic group, yet biological risk and protective factors underlying tobacco use in this ethnic group remain unknown. A genome scan for loci associated with tobacco use phenotypes was performed with data collected from a community sample of Mission Indians residing in Southwest California. 相似文献6.
7.
8.
Satellite cells express distinct patterns of myogenic proteins in immature skeletal muscle. 总被引:1,自引:0,他引:1
Edward Schultz Connie Chamberlain Kathleen M McCormick Paul E Mozdziak 《Developmental dynamics》2006,235(12):3230-3239
Satellite cells are the myogenic cells lying between the myofiber sarcolemma and basal lamina. The objective of this study was to determine the expression patterns of MyoD, myogenin, and Pax7 within the satellite cell population in the growing rat soleus and extensor digitorum longus (EDL) muscles. Secondly, the expression of the myogenic markers was also studied within the interstitial cell compartment and myonuclei. It was discovered that the soleus contained a higher number of Pax7, MyoD, or myogenin-positive nuclei compared with the EDL. Similarly, myogenin was expressed at a lower level in the myonuclei of the soleus compared with the EDL, and myogenin was expressed at a higher level in the interstitial compartment of the soleus compared with the EDL. When interstitial nuclei, myonuclei, and double-labeled nuclei were used in the estimate of the satellite cell population, it was discovered that approximately of 13% of the myofibers in a transverse section of the soleus muscle and 4.1% of EDL myofibers exhibit a labeled satellite cell nucleus. Overall, results from this study suggest that expression patterns of these markers vary predictably among muscles with different growth dynamics and phenotypic characteristics. 相似文献
9.
Edwin H. Preston He Xu Kiran K. Dhanireddy Jonathan P. Pearl Frank V. Leopardi Matthew F. Starost Douglas A. Hale Allan D. Kirk 《American journal of transplantation》2005,5(5):1032-1041
CD154-specific antibody therapy prevents allograft rejection in many experimental transplant models. However, initial clinical transplant trials with anti-CD154 have been disappointing suggesting the need for as of yet undetermined adjuvant therapy. In rodents, donor antigen (e.g., a donor blood transfusion), or mTOR inhibition (e.g., sirolimus), enhances anti-CD154's efficacy. We performed renal transplants in major histocompatibility complex-(MHC) mismatched rhesus monkeys and treated recipients with combinations of the CD154-specific antibody IDEC-131, and/or sirolimus, and/or a pre-transplant donor-specific transfusion (DST). Therapy was withdrawn after 3 months. Triple therapy prevented rejection during therapy in all animals and led to operational tolerance in three of five animals including donor-specific skin graft acceptance in the two animals tested. IDEC-131, sirolimus and DST are highly effective in preventing renal allograft rejection in primates. This apparently clinically applicable regimen is promising for human renal transplant trials. 相似文献
10.